BRPI0414174A - moléculas de ligação nogo-a e o uso farmacêutico das mesmas - Google Patents

moléculas de ligação nogo-a e o uso farmacêutico das mesmas

Info

Publication number
BRPI0414174A
BRPI0414174A BRPI0414174-1A BRPI0414174A BRPI0414174A BR PI0414174 A BRPI0414174 A BR PI0414174A BR PI0414174 A BRPI0414174 A BR PI0414174A BR PI0414174 A BRPI0414174 A BR PI0414174A
Authority
BR
Brazil
Prior art keywords
binding molecule
nogo
human
pharmaceutical use
pharmaceutical
Prior art date
Application number
BRPI0414174-1A
Other languages
English (en)
Inventor
Carmen Barske
Stefan Frentzel
Anis Khusro Mir
Martin E Schwab
Alessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of BRPI0414174A publication Critical patent/BRPI0414174A/pt
Publication of BRPI0414174B1 publication Critical patent/BRPI0414174B1/pt
Publication of BRPI0414174B8 publication Critical patent/BRPI0414174B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MOLéCULAS DE LIGAçãO NOGO-A E O USO FARMACêUTICO DAS MESMAS". A presente invenção proporciona uma molécula de ligação que é capaz de se ligar a um polipeptídio NogoA humano, ou a NiG humano, ou a NiG-D20 humano ou a NogoA_342-357 humano com uma constante de dissociação < 1000 nM, um polipeptídio que codifica essa molécula de ligação; um vetor de expressão que compreende o referido polinucleotídeo; um sistema de expressão que compreende um polinucleotídeo capaz da produção e uma molécula de ligação; uma célula hospedeira isolada que compreende um sistema de expressão como definido acima; o uso de tal molécula de ligação como um produto farmacêutico especialmente para o tratamento de reparo de nervo; uma composição farmacêutica que compreende a referida molécula; e um método para o tratamento de doenças associadas com o reparo de nervos.
BRPI0414174A 2003-09-19 2004-09-17 anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica. BRPI0414174B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0321997.9A GB0321997D0 (en) 2003-09-19 2003-09-19 Organic compound
GB0321997.9 2003-09-19
PCT/EP2004/010489 WO2005028508A2 (en) 2003-09-19 2004-09-17 Nogo-a binding with enhanced affinity and pharmaceutical use thereof

Publications (3)

Publication Number Publication Date
BRPI0414174A true BRPI0414174A (pt) 2006-10-31
BRPI0414174B1 BRPI0414174B1 (pt) 2019-06-04
BRPI0414174B8 BRPI0414174B8 (pt) 2021-05-25

Family

ID=29266310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414174A BRPI0414174B8 (pt) 2003-09-19 2004-09-17 anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.

Country Status (25)

Country Link
US (2) US20090181023A1 (pt)
EP (3) EP2423225A3 (pt)
JP (1) JP2007527232A (pt)
KR (1) KR20060119982A (pt)
CN (1) CN1878792A (pt)
AR (1) AR045671A1 (pt)
AU (2) AU2004274164B2 (pt)
BR (1) BRPI0414174B8 (pt)
CA (1) CA2538725C (pt)
CO (1) CO5680457A2 (pt)
EC (1) ECSP066431A (pt)
GB (1) GB0321997D0 (pt)
IL (2) IL174145A (pt)
IS (1) IS8404A (pt)
MA (1) MA28088A1 (pt)
MY (2) MY161068A (pt)
NO (1) NO20061678L (pt)
NZ (1) NZ545679A (pt)
PE (1) PE20050949A1 (pt)
RU (1) RU2380377C2 (pt)
SG (1) SG146660A1 (pt)
TN (1) TNSN06085A1 (pt)
TW (1) TWI372060B (pt)
WO (1) WO2005028508A2 (pt)
ZA (1) ZA200601842B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
WO2006059959A1 (en) * 2004-12-01 2006-06-08 National University Of Singapore Nogo a protein fragments as neuronal network-interacting peptides
HRP20120851T1 (hr) * 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (pt) 2012-07-05 2015-05-08 Glaxo Group Ltd
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体
CN114470197B (zh) * 2022-02-16 2023-10-03 天津长和生物技术有限公司 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0383417B1 (en) 1989-02-13 1995-12-27 Schering Aktiengesellschaft Vampire bat salivary Plasminogen activator vPA-alpha 1
DE69942803D1 (de) * 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
AU2002357770B2 (en) * 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases

Also Published As

Publication number Publication date
NO20061678L (no) 2006-06-16
PE20050949A1 (es) 2005-12-16
MA28088A1 (fr) 2006-08-01
US20110008334A1 (en) 2011-01-13
ZA200601842B (en) 2007-09-26
BRPI0414174B1 (pt) 2019-06-04
TNSN06085A1 (en) 2007-10-03
NZ545679A (en) 2009-11-27
BRPI0414174B8 (pt) 2021-05-25
MY158078A (en) 2016-08-30
RU2380377C2 (ru) 2010-01-27
JP2007527232A (ja) 2007-09-27
IS8404A (is) 2006-04-10
AU2009200237B2 (en) 2011-05-19
AU2004274164B2 (en) 2009-02-05
CA2538725C (en) 2010-12-21
KR20060119982A (ko) 2006-11-24
WO2005028508A2 (en) 2005-03-31
AR045671A1 (es) 2005-11-02
IL174145A0 (en) 2006-08-01
US20090181023A1 (en) 2009-07-16
WO2005028508A3 (en) 2005-07-07
CA2538725A1 (en) 2005-03-31
GB0321997D0 (en) 2003-10-22
MY161068A (en) 2017-04-14
SG146660A1 (en) 2008-10-30
AU2009200237A1 (en) 2009-02-12
AU2004274164A1 (en) 2005-03-31
ECSP066431A (es) 2006-09-18
IL174145A (en) 2010-11-30
EP2423225A2 (en) 2012-02-29
TW200517123A (en) 2005-06-01
CN1878792A (zh) 2006-12-13
RU2006112849A (ru) 2007-12-20
TWI372060B (en) 2012-09-11
EP1668033A2 (en) 2006-06-14
EP2423225A3 (en) 2013-03-20
EP2248827A1 (en) 2010-11-10
IL203007A0 (en) 2011-08-01
CO5680457A2 (es) 2006-09-29
IL203007A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
EA201690946A1 (ru) Мутанты fgf21 и их применение
TR200003281T2 (tr) CD-23&#39;e karşı antikorlar, bunların türevleri ve terapötik kullanımları.
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
EA201100516A1 (ru) Fgf21 мутанты и их применение
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
BR112020006248A8 (pt) Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer
BRPI0414174B8 (pt) anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.
CY1114345T1 (el) Βελτιωμενα μορια προσδεσης του nogo-a και φαρμακευτικη χρηση αυτων
ATE532502T1 (de) Kosmetische zusammensetzung für das haar
BRPI0515893B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica.
UY30952A1 (es) Polimorfos de s,s-dioxido del acido 7-[3-cloro-6,11-dihidro-6-metildibenzo[c,f][1,2]tiazepin-11-ilamino]heptanoico y métodos para su preparacion y uso
BR112014024398A2 (pt) composição derivada de osteoprotegerina e uso desta
BR0315845A (pt) Compostos de pirazina como moduladores de crf

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.